SomaGenics has pioneered the discovery and development of a unique class of short interfering RNAs called sshRNAs. Structurally distinct from the more commonly used siRNAs and expressed shRNAs, they are short, chemically modified RNA sequences that are synthesized as single strands. SshRNAs have outstanding potency and possess attractive pharmacokinetic properties without undesirable immune stimulation.
MicroRNAs (miRNAs) are of increasing interest as potential biomarkers and drug targets. The ability to accurately quantify them from biofluids such as blood, urine, or saliva ("liquid biopsy") is crucial to realizing their potential in early disease detection, diagnosis, drug development, and selecting and following treatment.